Welcome to our dedicated page for BIOCORRX NEW news (Ticker: BICX), a resource for investors and traders seeking the latest updates and insights on BIOCORRX NEW stock.
BioCorRx Inc. (BICX) is a leading healthcare solutions company focused on transforming the lives of individuals grappling with alcohol and opioid addiction. Utilizing a proprietary recovery program, the company offers a long-lasting FDA-approved naltrexone implant that significantly reduces cravings. With a network of treatment centers across the United States, BioCorRx's program is comprehensive, affordable, and highly effective, fostering an improved quality of life for individuals in recovery.
BioCorRx Inc. (OTCQB: BICX), a developer of innovative substance abuse treatment programs, provided a business update for Q2 2024. Key highlights include:
1. Expansion of intellectual property portfolio with a new international patent from Israel for weight loss treatment using naltrexone implants.
2. A new USPTO patent for a novel compound potentially reducing opioid withdrawal symptoms.
3. A $11 million grant from NIDA for developing BICX104, a long-duration naltrexone implant for methamphetamine use disorder (MUD).
The company remains focused on addressing global unmet medical needs in obesity and substance abuse, with ongoing progress in development efforts and strategic priorities aimed at creating shareholder value.
FAQ
What is the current stock price of BIOCORRX NEW (BICX)?
What is the market cap of BIOCORRX NEW (BICX)?
What is BioCorRx Inc. (BICX) focused on?
What sets BioCorRx's recovery program apart?
How does BioCorRx approach addiction treatment?
What recent achievements has BioCorRx celebrated?
What partnerships does BioCorRx have?
How does BioCorRx impact the opioid public health crisis?
What is BioCorRx's subsidiary BioCorRx Pharmaceuticals focused on?
How does BioCorRx receive funding for its research and development efforts?
What makes BioCorRx's approach to addiction treatment unique?